No abstract

reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S141-S163 S159 were obtained from bibliography. When this preview doses overcame the applicable dose limits (DL) the number of days that the patient must follow restrictions of permanence with his relatives were calculated. Results. The variation coefficient (VC) of doses rates among patients was 70% although the VC for the implanted I-125 activity, was only 23%. For sleeping partner only 38% of treatments no required a period of restrictions of permanence. The maximum and average values were 153 and 40 days. Analogous values for pregnant and child < 2 year were 16%, 161 and 58 days. Analogous values for work partner were 80%, 68 and 18 days. Conclusions. The radiation exposures around patients after prostatic implants have variability. Systematic measurements of each patient in an individualized basis must be done. The 62% and 20% of treatments require period of restrictions to reduce sleeping partner and working partners doses bellow the DL. A spread sheet has been developed to calculate the day after each implant in which the domestic activities of the patient can be recovered.http://dx. Introduction.High Dose Rate Endobronchial Brachytherapy (HDR-EBB) alone or in combination with EBRT, has shown efficacy as a treatment for inoperable lung neoplasms. In Galicia, this therapeutic modality was launched in 2005 in our centre. Objectives. To describe our experience with this treatment since its inception to the present (7 years). Patients and methods. We evaluated the local control, survival and complications at both 1 month and 1 year of all cases treated in our hospital. A total of 37 tumours were treated in 31 patients, 84% male, mean age of 65 years. 71% of the tumours were located in the trachea or main bronchi and corresponded mostly (84%) with primary lung cancer. In 20 cases (64.5%) they had curative intent and 11 (35.5%) palliative intent. On 14 occasions, prior External Beam Radiation Therapy was used and in 7 cases was associated with other debulking methods. The treatment was applied in weekly fractions of 5 Gy. The total dose ranged from 10 to 30 Gy in exclusive treatments and 10 to 20 Gy when associated with EBRT. Results. Overall, after a month of treatment, there was clinical improvement in 73.7% and endoscopic improvement in 87%. For curative treatments, the complete response of the treated area was 70% at 1 month and 66.7% at 1 year. Median survival was 4 months (95% CI 1.8-6.1 months) for palliative treatments and 40 months (95% CI 25.9-54 months) for curative treatments. There were serious complications in 9.7% of cases, 1 massive hemoptysis, 1 severe bronchospasm and 1 severe arrhythmia. Conclusion. In our experience, the HDR-EBB, is an effective method for palliative treatment of lung cancer with an acceptable complication rate. The HDR-EBB with curative intent is a treatment to consider in selected cases. Our results are comparable to those reported by others.

Background: Over the last decade there has been an improvement on the outcome of multiple myeloma (MM) patients. In patients eligible for high-dose chemotherapy and autologous stem cell transplant (ASCT), the inclusion of bortezomib in induction chemotherapy (ICT) has significantly delayed disease progression. Several studies have shown that achieving a complete response (CR) after ASCT is a predictive factor for disease control, leading to improved progression-free survival (PFS) and overall survival (OS). Aims: Assessing the impact of depth of response before and after ASCT on PFS in a population of MM patients treated with ICT including bortezomib and identifying predictive/protective factors for disease progression. Methods: Retrospective study of MM patients admitted for ASCT between January 2015 and December 2017 treated in first line with VCd (bortezomib, cyclophosphamide, and dexamethasone) or VTd (bortezomib, thalidomide and dexamethasone). Demographic (gender, age), clinical and biological variables at diagnosis were collected, as well as response obtained before and at D+100 after ASCT, and time elapsed between ASCT and disease progression. Statistical analysis was performed using STATA software (V13). Results: A total of 53 MM patients in the first line setting were included in this study. 43.4% were male; median age at diagnosis was 60 years old (IQR, 40-72). Both groups (VCd and VTd) had similar baseline characteristics. Median follow-up after induction chemotherapy was 20.6 months. PFS of patients who achieved CR or very good partial response (VGPR) post-induction was 73.7%, versus 60% in patients who achieved partial response (PR) or lower (log-rank p = 0.07). Looking at different variables that could modify the time between ASCT and disease progression, we observed that ISS stage 3 is an independent predictive factor for disease progression (HR 3.1; p = 0.014), and obtaining CR/ VGPR at D+100 post-ASCT is an independent protective factor against disease progression (HR 0.2; p = 0.004). Summary/Conclusion: Despite the relatively short follow-up period, in this population of transplant-eligible MM patients, we have demonstrated that the depth of response after induction chemotherapy (VGPR/CR) is critical for a greater PFS, and that a profound reduction in tumor burden (VGPR/CR) after ASCT allows for prolonged disease control. However, ISS stage 3 is a risk factor for disease progression regardless of the obtained response.

Introduction: Over the last few years, novel agents-based combinations have been incorporated into the treatment of MM patients, particularly in relapse setting. However, these novel combinations have been evaluated in clinical trials and patients included represent a selected population. Patients in real life are usually older with comorbidities and disabilities and not allowed to be included in the trials, so, in real setting, is expected worse outcomes and shorter survival. The information about treatment burden in real life is scarce. The aim of our study was to analyze the outcome of MM patients in the real life outside clinical trials, in terms of treatment lines in a single institution setting, and to analyze the influence of comorbidities on the treatment burden. Material and methods: Medical records of MM patients treated at Txagorritxu hospital (Spain) between 2009 and January 2017 were retrospectively evaluated with the aim of mapping the course of patients as well as to investigate the factors that influence treatment-decisions at different stages of the disease. Results: 176 patients with MM were diagnosed from jan-2009 to jan-2017. Baseline patient's characteristics are presented in Table 1. The median age at diagnosis was 71 years (range 33.2-93), main of the patients where non-transplant eligible newly diagnosed MM (NTENDMM): 114 (65%). With a median follow-up of 25 months, 90.6% of newly diagnosed MM patients transplant-eligible (TENDMM) remain alive versus 65% NTENDMM patients (p value: 0.000)(figure 1). Overall, patients received a median of 2 lines of treatment, it should be noted that 86% of patients had received 3 or less lines of treatment and only 14% of the patients could receive more than 3 lines of therapy. To better evaluate treatment burden, we focused on deceased patients. At the time of analysis, 19% of TENDMM (12 patients) and 51.4% of in NTENDMM (57 patients) has died with a median time to death of 29.6 months and 18 months to death, respectively. Median lines of therapy for death patients TENDMM was 3.5 (range 1-8), with a 75 percentile of 5 lines of therapy, by contrast, death NTENDMM patients received a median of 2 lines of therapy (range: 1-6), with an 80 percentile of 3 lines of therapy (figure 2). In order to evaluate the influence of comorbidities in treatment burden for NTENDMM patients, CIRS score was estimated retrospectively. Median CIRS score was 5.5 (1-19). CIRS scale did not predict progression free survival (PFS) among the different groups: CIRS <4: 23.4 months; CIRS4-8: 25.1 months and CIRS> 8: 30.6 months (p: 0.819), however, interestingly CIRS scale predicted overall survival (OS): CIRS <4: 48 moths; CIRS4-8: 50.8 months and CIRS> 8: 12.3 months, (p: 0.012) (figure 2). Analyzing treatment burden for each CIRS score group 63% of patients with CIRS> 8 received only one line of treatment before death, compared to 39.5% and 37.5% of patients with CIRS4-8 and CIRS <4, respectively. Conclusion: Although the impressive progress in the management of relapse/refractory MM patients in recent years, half of the patients, particularly those not suitable to received an autologous transplant, will be able to received only 2 lines of treatment before dying. In fact, an adequate comorbidity assessment could select patients that will only need only one line of treatment. To the best of our known, this is the first study that correlate treatment burden according to comorbidities at diagnostic. This study could guide strategies adapted according to the comorbidity of the patients. Disclosures No relevant conflicts of interest to declare.

cohort, suggesting potential overlap with immunodeficiency seen with CLL/SLL pts. Most surprisingly is the high rate of infusion related reactions; however, these were mainly confined to grade 2 reactions and grade 3 reactions were much lower than in the CLL11 trial (Goede V, NEJM 2014). While PFS is shorter compared to CLL11, this reflects both pts not completing therapy, as well as including pts in the r/r setting. Regardless, OBI remains an effective and well tolerated agent in both frontline and r/r pts with CLL/SLL who may not be eligible for other therapies.ABSTRACT 379